Lexicon Pharmaceuticals Reports Third Quarter 2022 Financial Results And Provides Business Update
Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended September 30, 2022 and provided an update on key corporate milestones
By Lexicon Pharmaceuticals, Inc.
Published - Nov 09, 2022, 04:05 PM ET
Last Updated - Mar 25, 2024, 11:29 AM EDT
NDA for Sotagliflozin Remains on Track for May 2023 PDUFA Date Following Mid-Cycle Review Meeting
Final Data from Successful RELIEF-DPN-1 Study of LX9211 in Painful Diabetic Neuropathy to Be Presented at 16thAnnual Pain Therapeutics Summit Next Week
Conference Call and Webcast at 5:00 pm Eastern Time
THE WOODLANDS, Texas, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today reported financial results for the three months ended September 30, 2022 and provided an update on key corporate milestones.
